BeiGene Ltd. (BGNE) saw its shares surge 5.24% on Wednesday, outperforming the broader market, after the European Commission approved the company's cancer treatment TEVIMBRA (tislelizumab) for expanded use in the region.
The approval allows TEVIMBRA, in combination with chemotherapy, to be used as a first-line treatment for adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The decision was based on positive results from two Phase 3 studies that demonstrated a statistically significant overall survival benefit for patients treated with TEVIMBRA plus chemotherapy.
Investors welcomed the regulatory approval, which expands the addressable market for BeiGene's cornerstone solid tumor therapy. The company highlighted the urgent need for effective treatment options in these cancer types, citing the poor prognosis for patients diagnosed with advanced gastric and esophageal cancers.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。